Smith MR - Search Results

1

Treatment and prevention of bone complications from prostate cancer.

Lee RJ, Saylor PJ, Smith MR. Lee RJ, et al. Among authors: smith mr. Bone. 2011 Jan;48(1):88-95. doi: 10.1016/j.bone.2010.05.038. Epub 2010 May 31. Bone. 2011. PMID: 20621630 Free PMC article. Review.

2

Osteoporosis during androgen deprivation therapy for prostate cancer.

Smith MR. Smith MR. Urology. 2002 Sep;60(3 Suppl 1):79-85; discussion 86. Urology. 2002. PMID: 12231056 Review.

3

Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer.

Smith MR. Smith MR. Cancer Metastasis Rev. 2002;21(2):159-66. doi: 10.1023/a:1020840311573. Cancer Metastasis Rev. 2002. PMID: 12465755 Review.

4

Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study.

Pirl WF, Siegel GI, Goode MJ, Smith MR. Pirl WF, et al. Among authors: smith mr. Psychooncology. 2002 Nov-Dec;11(6):518-23. doi: 10.1002/pon.592. Psychooncology. 2002. PMID: 12476433

5

Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma.

Smith MR. Smith MR. Cancer. 2003 Feb 1;97(3 Suppl):789-95. doi: 10.1002/cncr.11149. Cancer. 2003. PMID: 12548577 Free article. Review.

6

Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer.

Smith MR, Fallon MA, Goode MJ. Smith MR, et al. Urology. 2003 Jan;61(1):127-31. doi: 10.1016/s0090-4295(02)02006-x. Urology. 2003. PMID: 12559282

7

Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer.

Smith MR. Smith MR. Drugs Aging. 2003;20(3):175-83. doi: 10.2165/00002512-200320030-00002. Drugs Aging. 2003. PMID: 12578398 Review.

8

The role of bisphosphonates in the management of metastatic prostate cancer.

Michaelson MD, Smith MR. Michaelson MD, et al. Among authors: smith mr. Curr Oncol Rep. 2003 May;5(3):245-9. doi: 10.1007/s11912-003-0117-4. Curr Oncol Rep. 2003. PMID: 12667423 Review.

9

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Smith MR, et al. J Urol. 2003 Jun;169(6):2008-12. doi: 10.1097/01.ju.0000063820.94994.95. J Urol. 2003. PMID: 12771706 Clinical Trial.

10

Management of treatment-related osteoporosis in men with prostate cancer.

Smith MR. Smith MR. Cancer Treat Rev. 2003 Jun;29(3):211-8. doi: 10.1016/s0305-7372(03)00076-8. Cancer Treat Rev. 2003. PMID: 12787715

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,175 results

Search Page

Filters